Eligo Bioscience
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 4 to 11, 2027 · next Jan 4
- 1 fee due Feb 28, 2027The maintenance fee for Production of lytic phages (US 11,739,304) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Microbiome Modulation of a Host by Delivery of DNA Payloads with Minimized Spread (US 11,746,352) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Phage-Derived Particles for in Situ Delivery of DNA Payload into C. Acnes Population (US 11,820,989) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 2 fees due Jun 12, 2027
- 1 fee due Sep 26, 2027The maintenance fee for Production bacterial cells and use thereof in production methods (US 11,939,598) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 4 fees due Oct 9 to 30, 2027 · next Oct 9
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,357,831 | Sequence-Specific Antimicrobials by Blocking DNA Repair In force · High confidence | In force | High confidence | |
| US 12,214,022 | Sequence-Specific Antimicrobials by Blocking DNA Repair In force · Medium confidence | In force | Medium confidence | |
| US 11,124,776 | Pharmaceutical Compositions Comprising Bacterial Delivery Vehicles and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,952,594 | Pharmaceutical Compositions Comprising Bacterial Delivery Vehicles and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,236,133 | Chimeric Receptor Binding Proteins for Use in Bacterial Delivery Vehicles In force · High confidence | In force | High confidence | |
| US 11,512,116 | Chimeric Receptor Binding Proteins for Use in Bacterial Delivery Vehicles In force · High confidence | In force | High confidence | |
| US 12,729,223 | Chimeric Receptor Binding Proteins for Use in Bacterial Delivery Vehicles In force · High confidence | In force | High confidence | |
| US 11,970,716 | Transcriptional Control in Prokaryotic Cells Using DNA-Binding Repressors In force · High confidence | In force | High confidence | |
| US 11,421,222 | Bacterial delivery vehicles comprising tracer nucleic acid sequences In force · From the USPTO record | In force | From the USPTO record | |
| US 11,584,918 | Transcriptional Control in Prokaryotic Cells Using DNA-Binding Repressors In force · High confidence | In force | High confidence |
Also on record, not counted in the 33: 5 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 4 abandoned · 8 no status recorded